April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Antiangiogenic efficacy of intravitreal aflibercept versus ranibizumab in a fixed and a PRN-guided regimen in the VIEW2 trial
Author Affiliations & Notes
  • Sebastian M Waldstein
    Christian-Doppler-Laboratory for Ophthalmic Image Analysis, Vienna Reading Center, Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Christian Simader
    Christian-Doppler-Laboratory for Ophthalmic Image Analysis, Vienna Reading Center, Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Giovanni Staurenghi
    Eye Clinic - Department of Clinical Science “Luigi Sacco”- Sacco Hospital, II School of Ophthalmology, University of Milan, Milan, Italy
  • Michael Larsen
    Department of Ophthalmology, Glostrup Hospital and National Eye Clinic, University of Copenhagen, Copenhagen, Denmark
  • Paul Mitchell
    Department of Ophthalmology, University of Sydney, Sydney, NSW, Australia
  • Ursula Schmidt-Erfurth
    Christian-Doppler-Laboratory for Ophthalmic Image Analysis, Vienna Reading Center, Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships Sebastian Waldstein, None; Christian Simader, None; Giovanni Staurenghi, Alcon (C), Allergan (C), Bayer (C), Boehringer (C), Carl Zeiss Meditec (C), Genentech (C), GSK (C), Heidelberg Engineering (C), Heidelberg Engineering (F), Novartis (C), Ocular Instruments (P), OD-OS (C), OD-OS (F), Optos (C), Optos (F), QLT (C), Quentel Medical (C), Quentel Medical (F), Roche (C); Michael Larsen, Alcon (F), Allergan (F), Bayer (F), GlaxoSmithKline (F), Novartis (C), Novartis (F), Pfizer (C), Pfizer (F), Thrombogenics (C); Paul Mitchell, Bayer (C), Novartis (C), Pfizer (C); Ursula Schmidt-Erfurth, Alcon (C), Bayer (C), Boehringer (C), Novartis (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3959. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sebastian M Waldstein, Christian Simader, Giovanni Staurenghi, Michael Larsen, Paul Mitchell, Ursula Schmidt-Erfurth; Antiangiogenic efficacy of intravitreal aflibercept versus ranibizumab in a fixed and a PRN-guided regimen in the VIEW2 trial. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3959.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the impact of aflibercept versus ranibizumab treatment on the intraretinal, subretinal and sub-pigment epithelial (sub-RPE) pathomorphologic compartments using optical coherence tomography (OCT) in the VIEW2 trial.

Methods: In the VIEW2 trial, 906 patients with treatment-naïve neovascular age-related macular degeneration (AMD) were randomized to receive intravitreal aflibercept 2.0mg injections or ranibizumab 0.5mg treatment in a fixed monthly or bimonthly (Week 0-48) and subsequent pro re nata (PRN) (Week 52-96) regimen (with mandatory dosing quarterly). Standardized monthly OCT evaluation was performed by an independent certified reading center (Vienna Reading Center, VRC) for three major morphological parameters: intraretinal fluid/cysts (IRC), subretinal fluid (SRF) and pigment-epithelial detachment (PED).

Results: At baseline, the presence of IRC, SRF and PED was balanced between the treatment arms, with approximately 65% of eyes presenting with IRC, 86% with SRF and 80% with PED. After 3 initial monthly doses, the rates of IRC, SRF and PED had decreased to 21%, 27% and 55% respectively with ranibizumab treatment, and to 18%, 16% and 54% respectively with aflibercept treatment. In SRF and IRC, resolution rates and the differences between aflibercept and ranibizumab were maintained over time throughout the first study year with a fixed regimen. While the proportion of PED remained stable with ranibizumab, PED decreased continuously with aflibercept treatment in the monthly as well as the bimonthly regimen. During the PRN regimen however, recurrence of PED together with IRC was observed and IRC recurrence was associated with BCVA loss. Synchronized spikes in fluid recurrence were seen in all three compartments with the bimonthly and quarterly retreatment pattern.

Conclusions: Intravitreal aflibercept demonstrated a significantly superior drying effect in all retinal and sub-RPE compartments compared to ranibizumab. Although bimonthly aflibercept was equally effective as monthly treatment in terms of visual acuity, an increase in lesion activity was detected on OCT following treatment-free periods with progressive functional loss with PED and IRC reccurrence.

Keywords: 412 age-related macular degeneration • 550 imaging/image analysis: clinical • 453 choroid: neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×